Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

With gains of 8.8%, Hims & Hers Health was one of the winners on Wall Street today. Its shares are now trading at $50.34 and ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

This growth stock experienced a significant decline in stock price following an announcement with a key partner. *Stock prices used were the afternoon prices of June 23, 2025. The video was published ...

No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...